23.9 C
New York

Tag: Eli Lilly and Co

Egyptian archaeologists have uncovered a series of nearly...
Artificial intelligence will be used on the NHS app to determine which service is most appropriate for patients in England, the health service has announced.A new triage tool will ask patients a series of questions, and...

Amazon launches GLP-1 weight loss program, promising ‘fast, convenient’ access

Amazon GLP-1 treatmentSource: Amazon Inc. Amazon is pushing deeper into the booming weight loss market, unveiling Tuesday a new program that aims to simplify...

Novo Nordisk partners with OpenAI as AI drug discovery hopes mount 

Novo Nordisk is partnering with OpenAI to "bring new and better treatment options to patients faster," the Danish drugmaker said Tuesday. The partnership will enable...

Novo Nordisk’s explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment

After years of trying to lose weight "the right way," Jane Zuckerman realized that "putting in the work just wasn't enough." Zuckerman, a 32-year-old data...

Stocks soar on hopes of Iran war resolution — plus, Lilly takes a big swing in sleep disorders

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour...

Eli Lilly shares slide after a bearish Wall Street analyst call — here’s our view

Eli Lilly shares are down 6% Tuesday and on pace for their worst day since February after an HSBC downgrade. The crux of HSBC's...

Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026.Tom Little | ReutersNovo...

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026.George Frey | Bloomberg | Getty ImagesThe future...

Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here...

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Jim Cramer says don't sweat Novo Nordisk's head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about...

Eli Lilly hits $1 trillion market value, a first for a health-care company

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024.Scott Olson | Getty ImagesEli...

Eli Lilly Alzheimer’s treatment solanezumab failed to slow disease progression

Eli Lilly on Wednesday said it will halt development of its Alzheimer's treatment candidate solanezumab after the antibody failed to slow disease progression.Solanezumab's failure...

Recent articles

spot_img